Lisa M. Leschek-Gelman, MD

General Neurology
Specialties: Sleep Medicine, Epilepsy, and EEG

Dr. Lisa M. Leschek-Gelman, M.D. joined Abington Neurological Associates in 2021. After earning her M.D. and completing an internal medicine internship at Medical College of Pennsylvania, she went on to complete a neurology residency at Thomas Jefferson University Hospital and served as chief neurology resident at Hahnemann University Hospital. At Allegheney University of the Health Sciences, she completed a Clinical Neurophysiology Fellowship with an emphasis in epilepsy and EEG.

Dr. Leschek-Gelman has practiced medicine in the Christiana Care Health System, where she served as director of the EEG laboratory, and at Tower Health Medical Group, where she served as Division Chief in Neurology as well as EEG laboratory director. She is board certified in Neurology, Epilepsy, Sleep Medicine, and Clinical Neurophysiology, and is a member of the American Academy of Neurology, the American Epilepsy Society, and the American Clinical Neurophysiology Society.

Dr. Leschek-Gelman has conducted clinical trials and published papers on pharmacotherapy in epilepsy patients. She has given lectures to audiences of students, residents, and peers regarding a range of subjects in neurology, including multiple sclerosis, sleep disorders, migraine, and epilepsy.


Electroencephalography (EEG)

Electroencephalography, or EEG, monitors the brain's electrical activity through the skull to help diagnose epilepsy and other disorders that affect the brain's activity. This painless, risk-free test is performed by a certified EEG technician and interpreted by a board-certified epileptologist.


Abington Neurological Associates

Dr. Leschek-Gelman is on the team of physicians at Abington Neurological Associates, one of the largest private neurology practices in Montgomery and Bucks County. ANA has provided high quality comprehensive neurological care to the community for over 50 years.

Aducanumab Update

While various opinions are circulating, and the benefits of this drug are unclear, ANA will continue to monitor the situation and provide updates as information becomes available.
Read More